UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Assess whether a Total Market Fund Outperform SP 500 in Retirement by examining diversification, fees, and long-term performance to guide your strategy.
28,302 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
What if you could stack two reliable income engines at once? This guide shows how blending rental properties with pri...
A straightforward ETF that tracks corn futures is outperforming the S&P 500 in a choppy market, highlighting how non-...
Bitcoin sits roughly 43% below its all-time high as macro headwinds and fund outflows weigh on sentiment. This report...
Kansas faces a pivotal choice on property tax reform. This article outlines why neutrality matters, how distortions c...
Three leading tech ETFs battle for AI-era glory. This story breaks down Nvidia exposure, valuation, and risk to answe...
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
When markets turn sour, some energy stocks stand out for safety and reliability. This guide highlights two midstream ...
As crypto markets swing, STRC's flagship preferred shares are drawing more attention from everyday investors. This pi...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
Vanguard's VTWO and iShares' IWM both mirror the Russell 2000, but over 10 years VTWO's return outpaces IWM by roughl...
June 2026 brings a surprising shift: the market shows the strongest sign housing market signals in years. This articl...